Sees “confident” in this target, with revenue anticipated to be driven by the products’ best-in-class attributes, continued new prescription growth, and total prescription growth, which the company is seeing no signs of slowing down in Q3. Guidance taken from Harrow’s (HROW) Investor Day 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Morning Movers: Pharma, truck stocks react to Trump tariff announcements
- Harrow Health Acquires Melt Pharmaceuticals for Expansion
- Harrow enters agreement to acquire Melt Pharmaceuticals
- Harrow to hold analyst and investor day
- Harrow Health’s Strategic Debt Restructuring and Acquisition Propel Buy Rating